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Objective: Non-alcoholic fatty liver disease (NAFLD) is a complex pathology in which several dysfunctions, including alterations in metabolic
pathways, mitochondrial functionality and unbalanced lipid import/export, lead to lipid accumulation and progression to inﬂammation and ﬁbrosis.
The enzyme glycine N-methyltransferase (GNMT), the most important enzyme implicated in S-adenosylmethionine catabolism in the liver, is
downregulated during NAFLD progression. We have studied the mechanism involved in GNMT downregulation by its repressor microRNA miR-
873-5p and the metabolic pathways affected in NAFLD as well as the beneﬁt of recovery GNMT expression.
Methods: miR-873-5p and GNMT expression were evaluated in liver biopsies of NAFLD/NASH patients. Different in vitro and in vivo NAFLD murine
models were used to assess miR-873-5p/GNMT involvement in fatty liver progression through targeting of the miR-873-5p as NAFLD therapy.
Results: We describe a new function of GNMT as an essential regulator of Complex II activity in the electron transport chain in the mitochondria.
In NAFLD, GNMT expression is controlled by miR-873-5p in the hepatocytes, leading to disruptions in mitochondrial functionality in a preclinical
murine non-alcoholic steatohepatitis (NASH) model. Upregulation of miR-873-5p is shown in the liver of NAFLD/NASH patients, correlating with
hepatic GNMT depletion. Importantly, NASH therapies based on anti-miR-873-5p resolve lipid accumulation, inﬂammation and ﬁbrosis by
enhancing fatty acid b-oxidation in the mitochondria. Therefore, miR-873-5p inhibitor emerges as a potential tool for NASH treatment.
Conclusion: GNMT participates in the regulation of metabolic pathways and mitochondrial functionality through the regulation of Complex II activity
in the electron transport chain. In NAFLD, GNMT is repressed by miR-873-5p and its targeting arises as a valuable therapeutic option for treatment.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Non-alcoholic fatty liver disease (NAFLD) is the most common cause of
chronic liver disease. There are 7.5 billion people in the world, among
which it is estimated about 1.8 billion people (25%) suffer from NAFLD,
making it an emerging global health problem [1]. NAFLD progresses
from simple lipid accumulation (steatosis), which is considered a
benign disease, to non-alcoholic steatohepatitis (NASH) with inﬂam-
mation and ﬁbrosis, representing a major risk factor for the develop-
ment of cirrhosis and liver cancer [2]. Hepatic steatosis can result from
different non-excluding metabolic dysregulation, including i) impaired
lipid uptake; ii) alterations in mitochondrial fatty acid b-oxidation (FAO);
iii) increased de novo lipogenesis (DNL); iv) and/or inefﬁcient very-low-
density lipoprotein (VLDL) assembly and secretion.
Currently, there are no approved therapies for NAFLD treatment.
Current treatments aim at managing different clinical conditions such
as obesity and hypertriglyceridemia. However, new therapies targeting
the underlying mechanisms that trigger NAFLD are under develop-
ment. Due to the expected increase both in NAFLD and NASH, the
NASH market is estimated to rise about 34% in the next decade,
reaching a global worth of $15 billion only in the United States [3].
Nevertheless, the development of multitarget therapies remains an
important goal for the treatment of NAFLD.
Glycine N-methyltransferase (GNMT) is the most important and
abundant S-adenosylmethionine (SAMe)-dependent methyltransferase
in the liver. The downregulation of GNMT has been described in several
manifestations of chronic liver disease, including NAFLD [4,5],
cholestasis [6,7], cirrhosis, and liver cancer [8,9]. Particularly, in
NAFLD patients, GNMT has been described as one of the top down-
regulated proteins [4,5], highlighting the importance of its down-
regulation as a driver of disease progression during the initial stages of
the disease. In a recent study, we described the microRNA miR-873-
5p as a negative posttranscriptional regulator of GNMT expression in
the liver that is involved in the progression of cholestasis and ﬁbrosis
[7]. Moreover, targeting miR-873-5p recovered GNMT expression and
protected from liver injury [7]. GNMT is predominantly expressed in
hepatocytes, where it accounts for about 1e3% of total cytosolic
proteins and it is responsible for SAMe catabolism [8]. Although it isMOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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cell compartments, such as mitochondria [10] and nuclei [11],
although it is unknown what roles the protein exerts in these
organelles.
In recent years, several studies have described the role of mitochondria
in NAFLD [12]. Mitochondria are one of the most important metabolic
organelles and responsible for most ATP production in hepatocytes.
Several important metabolic pathways are operative in the mito-
chondria, including FAO, the tricarboxylic acid (TCA) cycle, and
oxidative phosphorylation (OXPHOS) in the electron transport chain
(ETC). In NAFLD, a number of metabolic adaptations occur to coun-
teract fat accumulation in the liver [12]. Increased mitochondrial FAO
has been reported in NAFLD patients and murine models. However,
this can result in reactive oxygen species (ROS) overproduction,
leading to mitochondrial dysfunction and inﬂammation. Alterations in
the activity of the ETC complexes, ATP generation, and oxidative
metabolism have been reported in NAFLD pathogenesis [12]. Thus, a
number of studies indicate that targeting mitochondrial function during
NAFLD is a promising approach for the treatment of liver disease
patients [13].
In this work, we have evaluated GNMT repression by miR-873-5p in
the liver and its involvement in NAFLD. We describe increased hepatic
miR-873-5p levels and its correlation with GNMT downregulation in
NAFLD/NASH patients. MiR-873-5p upregulation was also observed in
different murine NAFLD models in which the effect of targeting its
expression was evaluated. We demonstrate that the efﬁcient repres-
sion of miR-873-5p in the liver of mice fed with a methionine choline
deﬁcient diet (MCDD) results in the recovery of GNMT levels in the
hepatocytes and, speciﬁcally, in the mitochondria, with protective ef-
fects against NAFLD. Mechanistically, we describe that the role of
GNMT mitochondrial is mediated through the interaction and regulation
of Complex II (CII) activity of the ETC. This process increased mito-
chondrial functionality and FAO while decreasing oxidative stress in the
liver, protecting from fatty liver progression.
In summary, we describe a new essential role of GNMT in the mito-
chondria and demonstrate that the recovery of hepatic GNMT levels by
targeting miR-873-5p emerges as a new therapeutic approach for a
broad spectrum NAFLD therapies.cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 41
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2.1. Human subjects
Liver biospecimens were obtained from obese patients diagnosed in
the Marqués de Valdecilla University Hospital (MVUH, Santander,
Spain). Patients were evaluated for NAFLD using multiple markers of
disease after exclusion of alcoholic disease and viral hepatitis infection.
The characteristics of these patients are described in Table 1. The
studies were performed in agreement with the Declaration of Helsinki
and national regulations. The hospital Ethics Committees approved the
study procedures and written informed consent was obtained from all
patients before inclusion in the study.
2.2. Animal experimentation
2.2.1. miR-873-5p inhibition
Male 3-month old C57BL/6 mice were fed a methionine (0.1%) and
choline (0%) deﬁcient diet (MCD diet) (Research Diets, USA) or regular
chow diet as a control group. After 1 week of feeding on the 0.1%MCD
diet, mice were treated with anti-miR-873-5p (60mg/mouse) (Dhar-
macon, USA) or an unrelated miR-Ctrl using Invivofectamine 3.0
Reagent (Thermo Fisher Scientiﬁc, Massachusetts, USA) by tail vein
injection every 3e4 days until 4 weeks. At the end of the experiment,
mice were sacriﬁced, and livers were snap frozen or ﬁxed in formalin
for subsequent analysis or subjected to different ex vivo analysis of b-
oxidation and de novo lipogenesis. Male 4-month old Gnmt-KO mice
fed a regular chow diet were treated with a single dose of the anti-miR-
873-5p (60ug/mouse) by tail vein injection. Mice were sacriﬁced 4
days later, and livers were snap frozen, ﬁxed in formalin, or used for
ex vivo analysis of b-oxidation. At least ﬁve (n 5) animals were used
per group. Animal procedures were approved by CIC bioGUNE’s Animal
Care and Use Committee and the competent authority (Diputación de
Bizkaia).
2.2.2. Liver lipid quantiﬁcation
30 mg of frozen livers were homogenized with ice-cold PBS. Fatty
acids were measured in the homogenates using the Wako Chemicals
kit (Richmond, VA, USA), and lipids were extracted and quantiﬁed as
described [14]. Phosphatidilcholine (PC), phosphatidylethanolamine
(PE), fatty acids (FAs), and cholesterol (Ch) were separated by thin layer
chromatography (TLC) and quantiﬁed as described [15]. TriglyceridesTable 1 e Characteristics of obese patients included in NAFLD analysis.
Abbreviations: BMI (body mass index), TG (triglycerides), LDL/HDL (low/high
density lipoprotein).
Variable Healthy Steatosis NASH
N 6 20 16
Age (years, mean  SD) 31.6  5.5 44.6  11.1 49  11
Gender (F/M) 7/0 11/9 9/7
BMI 48.6  5.4 47.9  5.6 47  5.7
TG 134.8  93.4 170.3  100.4 181.6  84.7*
Cholesterol 190  36.6 172.2  40.3 187.5  32.8
LDL 110.8  35 91.6  29.6 106.8  28
HDL 55.3  12.9 41  10 38.3  9
AST 18.4  4.1 27.6  13 33  20.5
ALT 18.5  7.5 34.1  19.6 40.5  22.5
Glucose 85.8  6.5 107.3  38.9 115.7  42*
NAS score 0.6  0.1 2.63  0.25 4.56  0.27*
Ballooning 0.2  0.1 0.42  0.2 1.44  0.13*
Inﬂammation 0.4  0.13 0.58  0.2 1  0.6*
* p < 0.05 compared to healthy subjects.
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2.2.3. b-oxidation
Fatty acid b-oxidation was assessed as described before [16e18].
Fresh liver slices were homogenized in cold buffer (TriseHCl 25 mM,
sucrose 500 nM, EDTA Na2 pH 7.4 1 mM), sonicated (1000), and
centrifuged (500 g, 100, 4 C). 500 mg of protein were diluted in
200 ml. The assay was performed as follows: 400 ml of assay mixture
containing 0.5 mCi/ml (1e14C) palmitate was added to the samples
and incubated 1 h at 37 C in Eppendorf tubes with a Whatman paper
in the cap. The reaction was stopped by adding 400 ml of perchloric
acid 3M, and NaOH 1M was added to impregnate the Whatman cap.
After 2 h, the Whatman cap was retired, and the radioactivity asso-
ciated was measured in a scintillation counter. Eppendorf tubes were
centrifuged (2100 g, 10’, 4 C). 400 ml of the supernatant were
collected and the radioactivity was counted in a scintillation counter.
2.2.4. De novo lipogenesis
DNL was performed as previously described [19] with slight modiﬁ-
cations. Brieﬂy, freshly isolated liver tissue slices (40 mg) were
incubated in high glucose DMEM with insulin (150 nM) and [3H]- Acetic
acid 20 mCi/ml for 4 h. Tissue slices were washed and homogenized in
PBS. Then, lipids were extracted [14] and separated [15] as previously
described. Each lipid was scraped and the radioactivity was measured
in a scintillation counter.
2.2.5. Succinate dehydrogenase (SDH) activity
SDH activity was measured in mitochondrial frozen liver extracts with
Succinate Dehydrogenase Activity Colorimetric Assay Kit (MAK197,
Sigma Aldrich) following the manufacturer’s procedure. SDH activity
was calculated and represented as nmol of succinate converted to
fumarate/(volume/minute).
2.2.6. Lipid peroxidation
Lipid peroxidation Assay kit: Malondialdehyde (MDA) content in liver
samples was quantiﬁed by using a commercially available kit from
SigmaeAldrich (St. Quentin Fallavier, France) and quantiﬁed colori-
metrically (OD ¼ 532 nm).
2.2.7. Mitochondrial isolation
Liver mitochondria were freshly isolated by differential centrifugation
followed by rapid centrifugation through Percoll density gradient as
previously described [20]. Alternatively, mitochondria from frozen
livers were obtained using the Mitochondrial/Cytosol Fractionation Kit,
Abcam (London, UK).
2.2.8. Blue native-PAGE
Puriﬁed mitochondria were solubilized in native PAGE loading buffer
(Invitrogen, USA) containing 2% digitonin (Sigma, USA). Complexes
were resolved by electrophoresis in 3e12% NativePAGE Novex Bis-
Tris gels (Invitrogen) followed by transfer to a polyvinylidene diﬂuor-
ide (PVDF) membrane and western blot analysis.
2.2.9. Protein immunoprecipitation assay
ProteineProtein complexes were immunoprecipitated as described
before [21] using Complex II Immunocapture Kit (ab109799) (Abcam).
2.2.10. Metabolomic analysis
Metabolites implicated in the methionine cycle and reduced/oxidized
glutathione were determined by LC/MS using a Waters ACQUITY-UPLChis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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system coupled to a Waters Micromass LCT Premier Mass Spec-
trometer equipped with a Lockspray ionization source as described
previously [22].
2.2.11. Protein isolation and western blotting
Total protein extracts from primary hepatocytes and hepatic tissue
were resolved in sodium dodecyl sulfate-polyacrylamide gels and
transferred to nitrocellulose membranes. As secondary antibodies, we
used anti-rabbit-IgG-HRP-linked (Cell Signaling) and anti-mouse-IgG-
HRP-linked (Cell Signaling).
2.2.12. Proteomic analysis
Proteomic analysis in freshly isolated liver mitochondria was per-
formed following the label free (LF) analysis. Protein was extracted
using 7M urea, 2M thiourea, 4% CHAPS. Samples were incubated for
30 min at RT under agitation and digested following the ﬁlter-aided
FASP protocol [23]. Approximately 500 ng of each sample was sub-
mitted to liquid chromatography-mass spectrometry (LC-MS) label-
free analysis. Peptide separation was performed on a nanoACQUITY
UPLC System (Waters) on-line connected to an LTQ Orbitrap XL mass
spectrometer (Thermo Electron). An aliquot of each sample was loaded
onto a Symmetry 300 C18 UPLC Trap column (180 mm  20 mm,
5 mm (Waters)). The precolumn was connected to a BEH130 C18
column (75 mm  200 mm, 1.7 mm (Waters), and equilibrated in 3%
acetonitrile and 0.1% FA. Peptides were eluted directly into an LTQ
Orbitrap XL mass spectrometer (Thermo Finnigan) through a nano-
electrospray capillary source (Proxeon Biosystems), at 300 nl/min and
using a 120 min linear gradient of 3e50% acetonitrile. The mass
spectrometer automatically switched between MS and MS/MS
acquisition in DDA mode. Full MS scan survey spectra (m/z 400e
2000) were acquired in the orbitrap with mass resolution of
30000 at m/z 400. After each survey scan, the six most intense ions
above 1000 counts were sequentially subjected to collision-induced
dissociation (CID) in the linear ion trap. Precursors with charge
states of 2 and 3 were speciﬁcally selected for CID. Peptides were
excluded from further analysis during 60 s using the dynamic exclusion
feature.
Progenesis LC-MS (version 2.0.5556.29015, Nonlinear Dynamics) was
used for the label-free differential protein expression analysis. One of
the runs was used as the reference to which the precursor masses in
all other samples were aligned to. Only features comprising charges of
2þ and 3þ were selected. The raw abundances of each feature were
automatically normalized and logarithmized against the reference run.
Samples were grouped in accordance to the comparison being per-
formed, and an ANOVA analysis was performed. A peak list containing
the information of all the features was generated and exported to the
Mascot search engine (Matrix Science Ltd.). This ﬁle was searched
against a Uniprot/Swissprot database, and the list of identiﬁed peptides
was imported back to Progenesis LC-MS. Protein quantitation was
performed based on the three most intense non-conﬂicting peptides
(peptides occurring in only one protein), except for proteins with only
two non-conﬂicting peptides. The signiﬁcance of expression changes
was tested at protein level, and proteins with an ANOVA p-value 
0.05 were selected for further analyses.
Subsequent analysis and clustering of differentially expressed proteins
was performed using Perseus software platform (http://www.perseus-
framework.org) in order to group proteins according to changes in their
amount. Finally, GO enrichment analysis was carried out using the
STRING online tool (https://string-db.org/) in order to infer pathways
and processes altered in each group and cluster.MOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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reaction
Total RNA was isolated with Trizol (Invitrogen). 1e2 mg of total RNA
was treated with DNAse (Invitrogen) and reverse transcribed into cDNA
using M-MLV Reverse Transcriptase (Invitrogen). Quantitative real-time
PCR (RT-PCR) was performed using SYBR Select Master Mix (Applied
Biosystems) and the ViiA 7 Real-Time PCR System (Applied Bio-
systems) by the DDCt method using Arp as reference gene.
2.2.14. MicroRNA quantitative real-time PCR
RT-PCR was performed for miR-873-5p following a TaqManMicroRNA
Reverse Transcription Kit (Life Technologies, USA) procedure using
50 ng of total RNA. qPCR was performed with the TaqMan Universal PCR
Master Mix No AmpErase UNG kit following manufacturer’s procedure.
miR-873-5p expression levels were normalized to the U6 snRNA.
2.2.15. Immunohistochemistry
Parafﬁn embedded liver samples were sectioned, dewaxed, and hy-
drated. Immunohistochemistry was performed as previously described
[24]. H&E and Sirius red staining for collagen was performed in parafﬁn
embedded liver samples. F4/80 a membrane macrophage marker and
aSMA, a marker for activated stellate cells were analyzed by immu-
nohistochemical staining. Liver Sudan Red staining for the histological
quantiﬁcation of hepatic lipids was used. Stained area percentage of
each sample were calculated using FRIDA software (FRamework for
Image Dataset Analysis) http://bui3.win.ad.jhu.edu/frida/.
2.3. Cellular experiments
Mouse primary hepatocytes, Kupffer cells, and hepatic stellate cells
were isolated as previously described [25,26]. Brieﬂy, mouse livers
were perfused with collagenase (Worthington Biochemical Company,
Freehold, USA) and hepatocytes isolated following a standard centri-
fugation. KC ad HSC were isolated after Percoll Plus (GE Healthcare,
Little Chalfont, United Kingdom) gradient centrifugation and selective
adherence. Primary hepatocytes were isolated from C57BL/6 WT and
Gnmt-KO mice via collagenase as above mentioned and transfected
with anti-miR-873-5p or miR-Control using dharmaFECT1 transfection
reagent (Dharmacon) as previously described [7]. Hepatocytes were
cultured with oleic acid (OA, 400 mM 6 h) (Sigma Aldrich) or maintained
in medium deﬁcient in methionine and choline (MDMC) (48 h). Cellular
experiments were performed at least three times.
2.3.1. BODIPY staining
Hepatocytes in culture were collected in covers and incubated with
BODIPY 493/503 (Molecular Probes, Thermo Fisher Scientiﬁc) at a
concentration of 10 mg/ml during 45 min prior to ﬁxation (4% para-
formaldehyde). Quantiﬁcation of lipid bodies was performed using the
Frida Software (FRamework for Image Dataset Analysis) http://bui3.
win.ad.jhu.edu/frida/.
2.3.2. Respiration studies
The cellular metabolic proﬁle was determined using a Seahorse XF24
Extracellular Flux Analyzer (Seahorse Biosciences, USA), providing
real-time measurements of the oxygen consumption rate (OCR) as
previously described [27].
2.3.3. Reactive oxygen species (ROS)
ROS production in primary hepatocytes was assessed using CellROX
Deep Green Reagent (Thermo Fisher Scientiﬁc). The hepatocytes were
loaded with 1.5 mM CellROX in 10% FBS-MEM (10’, 37 C). Thecess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 43
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buffered saline, collected, and analyzed by ﬂow cytometry FACS
Canto II (BD Biosciences, USA).
2.4. Statistical analysis
Data are represented as average  SEM. For in vivo studies at least
ﬁve (n  5) animals were used per group. For in vitro cellular studies,
experiments were performed at least 3 times. mRNA/RNA data is
normalized vs. control. Statistical signiﬁcance was determined with
Prism 5 (GraphPad Software). One-way analysis of variance (ANOVA)
test was used when 3 groups were compared, while the Student’s t-
test was used for 2 group comparisons. A p < 0.05 was considered
signiﬁcant for all the comparisons except for proteomic analysis where
p-adj. (q value) q < 0.05 was considered.
3. RESULTS
3.1. GNMT and miR-873-5p expression in NAFLD
GNMT expression has been identiﬁed as part of an anti-steatotic
mechanism, and its reduction has been well documented in NAFLD
patients [4,5]. The mechanisms driving GNMT downregulation in
NAFLD and the potential beneﬁt of recovering normal GNMT levels in
the liver in NAFLD situations have not been previously addressed.
Recently, we have described the implication of miR-873-5p in GNMT
repression during ﬁbrosis and cholestasis [7]; thus, we have analyzed
the implication of this microRNA in early stages of NAFLD in associ-
ation with GNMT. Consistent with previous results [4,5], we found
GNMT was downregulated in the liver of NAFLD (N ¼ 36) compared to
healthy obese (N ¼ 6) subjects (Figure 1A). NAFLD patients were
divided as simple steatosis (20) or NASH (16) stages based on clinical
and histopathological features (Table 1). Conversely, miR-873-5p was
progressively increased in steatosis and mainly in NASH patients
(Figure 1B), correlating with GNMT reduction (Figure 1C). Moreover, we
found a correlation between GNMT and miR-873-5p expression in the
liver and the grade of ﬁbrosis progression (NAS score) and metabolic
parameters such as circulating glucose, TGs, and HDL levels in these
patients (Figure 1D). These results indicate a matched dysregulation of
GNMT, miR-873, and metabolism that correlates with NAFLD pro-
gression to more severe stages.
Gnmt and miR-873-5p regulation was also assessed in several murine
models of NAFLD. Gnmt reduction in association with miR-873-5p
upregulation was observed in mice fed for 4 weeks with a choline
deﬁcient and methionine-0.1% diet (MCDD), in those under a high fat
diet (HFD) for 20 weeks and in mice under high cholesterol diet (HCD)
for 4 weeks (Figure 1E). Even though these models differ from each
other in the mechanism underlying fatty liver progression and the
global metabolic effect, GNMT/miR-873-5p alterations observed in all
of them suggest this axis may be involved in the regulation of a
common metabolic pathway in the liver.
These data highlight the association between miR-873-5p and GNMT
expression in human and mice during NAFLD.
3.2. The rescue of GNMT expression by anti-miR-873-5p reduces
lipid accumulation in vitro in hepatocytes
As a chronic model of GNMT depletion, the Gnmt-KO mouse develops
steatosis and NASH spontaneously [28]. In this murine model, different
mechanisms associated with GNMT deﬁciency have been described
that contribute to the development of the disease [25,28e30]. Here,
we assessed the role of miR-873-5p in a steatotic in vitro model. As
GNMT is known to be mainly expressed in hepatocytes [8], we ﬁrst
studied the role of GNMT/miR-873-5p regulation in these cells under44 MOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. Tsteatotic conditions. Primary WT hepatocytes were incubated with oleic
acid (OA) (400 mM, 6 h) or with a medium deﬁcient in methionine and
choline (MDMC) for 48 h. miR-873-5p was upregulated in both con-
ditions (Figure 2A). Anti-miR-873-5p transfection (Suppl. Fig. 1A,B)
resulted in GNMT recovery (Figure 2B) and in the reduction in lipid
content, measured by the BODIPY staining (Figure 2C and
Suppl. Fig. 1A,B). Importantly, secretion of acid-soluble metabolites
(ASM) (Krebs cycle metabolites and ketones), as a measure of FA b-
oxidation revealed a signiﬁcant increase in cells treated with OA and
transfected with anti-miR-873-5p (Figure 2D). Consistent with these
results, the expression of genes associated with FA b-oxidation such
as Acadm, Acadl (acyl-CoA dehydrogenase, medium and long chain),
peroxisome-proliferator activated receptor alpha (Ppara), peroxisome
proliferator-activated receptor gamma coactivator 1 (Pgc1a) (impli-
cated in mitochondrial biogenesis and remodelling in most cells) and
NF-E2-related factor 2 (Nrf2), a transcription factor involved in anti-
oxidant defence, were upregulated in both models after blockade of
miR-873-5p (Figure 2E).
The oxygen consumption rate (OCR) revealed an increase of OXPHOS
by seahorse analysis in primary hepatocytes transfected with anti-miR-
873-5p (Figure 2F), as a surrogate of mitochondrial functionality.
Importantly, a reduction of oxidative stress (ROS) was detected in both
in vitro steatotic models under anti-miR-873-5p treatment (Figure 2G).
Finally, to prove the speciﬁc targeting of miR-873-5p over Gnmt,
Gnmt-KO hepatocytes were transfected with anti-miR-873-5p and
incubated with oleic acid (OA) (400 mM, 6 h). Importantly, anti-miR-
873-5p (Suppl. Fig. 1C) did not reduce lipid content in Gnmt-KO he-
patocytes, indicating the major role of Gnmt targeting by miR-873-5p
under steatotic condition in the hepatocytes (Suppl. Fig. 1C).
These results suggest a new effect of GNMT re-expression mediated
by anti-miR-873-5p on fatty acid b-oxidation concomitant with a better
mitochondrial functionality and a reduction in oxidative stress leading
to a lower accumulation of lipids in hepatocytes.
3.3. Anti-miR-873-5p treatment reduces steatohepatitis in vivo
Previous studies have shown GNMT is mainly found in hepatocytes;
however it is also expressed in other cells, such as macrophages
(Kupffer Cells and hepatic stellate cells) [7,8,31]. Thus, to better
characterize GNMT/miR-873-5p regulation in NAFLD progression, we
measured their expressionGnmt levels in different hepatic cell pop-
ulations freshly isolated from WT mice fed a chow or MCD diet during 4
weeks. According to previous studies Gnmt was found to be mainly
expressed in hepatocytes (Suppl. Figure 2A). Moreover, MCD diet only
resulted in Gnmt downregulation and miR-873-5p upregulation in
hepatocytes, suggesting the importance of this miRNA-protein in these
cells during NAFLD progression (Suppl. Figure 2A). These results are
also in accordance with our in vitro evidence regarding the beneﬁt of
recovering GNMT levels in hepatocytes (section 3.2).
In order to analyze the role of GNMT/miR-873-5p in a preclinical model
of NASH, mice were fed with a MCD diet for one week, when lipid
accumulation and inﬂammation is initiated in the liver and GNMT/miR-
873-5p misregulation is produced (Suppl. Figure B,C). The mice were
then injected with a miR-Control or an anti-miR-873-5p twice a week
for three more weeks under the MCD diet (Suppl. Figure 2D). Anti-miR-
873-5p treatment resulted in GNMT recovery in the liver (Figure 3Ae
C). Histological evaluation of H&E-stained liver tissue revealed a
decreased vacuolization of hepatocytes in anti-miR-873-5p-treated
mice (Figure 3D). The activation of hepatic stellate cells, assayed by
smooth muscle actin (SMA) staining, collagen deposition (Sirius red),
inﬂammation (F4/80) and inﬂammatory gene expression (Interleukin
1b (Il1b), Chemokine (CeC motif) ligand 2 (Ccl2), and Tumor necrosishis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: miR-873-5p inversely correlates GNMT downregulation in the liver in NASH. (AeC) miR-873-5p and GNMT expression and correlation in the liver of a cohort of steatotic
(n¼ 20) and NASH (n¼ 16) patients. (D) GNMT and miR-873-5p expression levels in the liver and correlation with (left to right) NAS score, and circulating levels of glucose, triglycerides
(TGs), total cholesterol, and low- and high-density lipoprotein (LDL, and HDL). (E) miR-873-5p and Gnmt expression in indicated murine models of NAFLD, from left to right: methionine
choline deﬁcient diet (MCDD); high fat diet (HFD) and high cholesterol diet (HCD). Data shown as average  SEM. p < 0.05 *; p < 0.01 **; p < 0.001 ***.factor receptor 1 (Tnfr1)); ALT aminotransferases levels were also
diminished in the livers of anti-miR873-5p-treated animals
(Figure 3DeF).
Moreover, Sudan red, which stains triglycerides and lipids, identiﬁed a
reduction of positively stained droplets in anti-miR873-5p mice
(Figure 3D). Furthermore, the biochemical determination of lipid con-
tent revealed reduced levels of triglycerides, FAs and cholesterol in the
livers of these mice (Figure 3G), while the levels of different types of
phospholipids (PLs) remained stable or slightly decreased
(Suppl. Fig. 3). Altogether, our results indicate that miR-873-5pMOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.cominhibition decreases lipid content alleviating liver inﬂammation and
ﬁbrogenesis, globally blunting NASH progression, which appears to be
mediated by the recovery of GNMT in the hepatocytes.
3.4. GNMT re-expression activates b-oxidation in vivo reducing
steatosis
Hepatic fat can be reduced through the activation of different path-
ways, including triglycerides secretion into VLDLs, enhanced fatty acid
b-oxidation (FAO) and/or decreased de novo lipogenesis (DNL).
Therefore, we further characterized the response observed under miR-cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 45
Original Article873-5p inhibition in the MCD diet mice. DNL measured by ex vivo [H3]
acetate incorporation revealed no differences in the hepatic formation
of FAs, PLs, free cholesterol, cholesterol ester, and TGs, after blocking
miR-873-5p (Figure 4A). Moreover, reduced TG in the serum sug-
gested decreased TG export into VLDLs in anti-miR-873-5p treated
mice (Figure 4B). These data indicate that miR-873-5p regulates lipid
metabolism through mechanisms different from DNL or VLDL secre-
tion, as previously suggested in our in vitro model, in which increased
FAO was shown in anti-miR-873-5p hepatocytes (section 3.2).
We therefore explored FAO as the main mechanism implicated in FA
degradation. [C114] palmitate labeling revealed an increase of the CO2Figure 2: In vitro targeting of miR-873-5p decreases lipid accumulation in hepatocyt
oleic acid (OA) or medium deﬁcient in methionine and choline (MDMC). (C) Quantiﬁcation of
b-oxidation and (E) qPCR analysis of b-oxidation related genes in primary hepatocytes. (F)
seahorse analysis. (G) ROS levels in primary hepatocytes treated with miR-Ctrl anti-miR-87
**; p < 0.001 ***.
46 MOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. Treleased as the index FAO in anti-miR-873-5p mice (Figure 4C).
Consistently, an increase in serum ketone bodies was detected
(Figure 4D). These results were further supported by the induction of
genes implicated in FAO, such as Acadm, Acadl, Ppara, and Pgc1a
(Figure 4E).
Fatty acid b-oxidation is directly linked to the ETC. In NAFLD, mito-
chondrial dysfunction impairs the oxidation of FAs as a consequence of
ROS production, leading to lipid accumulation within the liver. In vitro
results show that improved FAO in anti-miR-873-5p-hepatocytes do
not increase ROS and mitochondrial stress. Thus, we measured the
oxidative stress in MCD mice by two different approaches. Decreasedes. (A,B) miR-873-5p expression and GNMT levels in primary hepatocytes cultured with
BODIPY staining in primary mouse hepatocytes under indicated condition. (D) Analysis of
OCR measurement of primary mouse hepatocytes with anti-miR-873-5p or miR-Ctrl by
3-5p under indicated conditions. Data shown as average  SEM. p < 0.05 *; p < 0.01
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: miR-873-5p inhibition in vivo recovers GNMT expression and reduces lipid content, inﬂammation and ﬁbrosis in the liver of MCDD mice. (A) miR-873-5p
levels in MCDD mice after anti-miR-873-5p administration. (B) GNMT levels determined by WB and (C) IHC in MCDD mice. (D) Liver characterization by IHC with indicated
staining in MCDD mice showing H&E, lipid content (Sudan Red), inﬂammation (F4/80) and ﬁbrosis (aSMA and Sirius Red). (E) mRNA analysis of indicated genes related to in-
ﬂammatory response in liver extracts. (F) Serum biochemical analysis of transaminases (ALT and AST). (G) Quantiﬁcation of liver lipid content showing fatty acids, triglycerides, and
free cholesterol in the indicated MCDD mice. Data shown as average  SEM. p < 0.05 *; p < 0.01 **; p < 0.001 ***.lipid peroxidation measured by malondialdehyde (MDA), together with
the increase in reduced glutathione levels, the most important anti-
oxidant defense system (Figure 4F), conﬁrmed that anti-miR-873-5p
treatment reduces oxidative stress in the liver in the NASH model.
The role of GNMT in mitochondrial FAO capacity mediated by anti-miR-
873-5p treatment was further supported by the lack of effect of anti-
miR-873-5p in the absence of GNMT in the liver. In order to prove it, 4-
months old Gnmt-KO mice, when they have already developed liver
steatosis and inﬂammation [28], were treated with the anti-miR-873-
5p by tail vein injection four days, a time point in which miR-873-5p is
already efﬁciently inhibited in the liver (Suppl. Figure 4A). According toMOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comin vitro results in Gnmt-KO hepatocytes (Section 3.2), anti-miR-873-5p
treatment did not have any effect in lipid accumulation and NASH
development in the livers of Gnmt-KO mice (Suppl. Figure 4B).
Moreover, FAO measured by [C114] palmitate labeling revealed no
changes in CO2 released in anti-miR-873-5p Gnmt-KO mice
(Suppl. Figure 4C), further indicating the speciﬁc role of GNMT in the
regulation of mitochondrial FAO and its targeting by miR-873-5p in
NAFLD/NASH.
Altogether, these results conﬁrm the implication of anti-miR-873-5p
and GNMT in the induction of FAO as the main mechanism to
reduce lipid accumulation in NAFLD/NASH (Figure 4G).cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 47
Figure 4: Targeting miR-873-5p induces mitochondrial fatty acid b-oxidation. (A) Serum TG levels, (B) ex vivo determination of DNL and (C) mitochondrial FA b-oxidation
measured by CO2 oxidation, in control and MCDD livers. (D) Analysis of serum ketone bodies (KBs). (E) mRNA analysis of indicated genes related to FA b-oxidation in liver extracts.
(F) Analysis of oxidative stress in the MCDD livers measured by GSH and GSH/GSSG content and lipid peroxidation (MDA). (G) Schematic representation of the anti-miR-873-5p
effect in the liver of MCD diet mice. Data shown as average  SEM. p < 0.05 *; p < 0.01 **; p < 0.001 ***.
Original Article3.5. MiR-873-5p regulates mitochondrial GNMT and complex II
activity in NAFLD
GNMT is an abundant cytosolic enzyme that is also present in other
cellular compartments [10,11]. To understand the impact of anti-miR-
873-5p/GNMT in lipid metabolism related to FAO we evaluated the48 MOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. Tmitochondrial localization of GNMT in the MCDD fed mice. GNMT was
found in the mitochondrial fraction of healthy livers, while steatotic
feeding resulted in reduced mitochondrial GNMT. Remarkably, anti-
miR-873-5p counteracted GNMT decrease in the mitochondria
(Figure 5A and Suppl. Fig. 5A).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: Mitochondrial GNMT decrease drives disruptions in Complex II activity. (A) WB analysis of GNMT and (B) global proteomic proﬁle of freshly isolated liver
mitochondria in the MCDD and MCDD-anti-miR-873-5p mice compared to control diet mice, changes are presented as ratios by intensity (colour scale bar). (C) BN-PAGE of 2%
digitonin solubilized mitochondrial liver extracts, transferred to a membrane and immunoblotted for GNMT and SDHA. (D) Immunoprecipitation assay of mitochondrial liver extracts
immunocaptured with CII and blotted for GNMT. (E) CII activity assay performed in the liver of the MCDD and (F) in Gnmt-KO mice. Data shown as average  SEM. p < 0.05 *;
p < 0.01 **.At present, no mitochondrial function of GNMT has been described. To
characterize mitochondria in MCD diet mice, we performed proteomic
analysis of freshly isolated liver mitochondria, to determine potential
processes regulated by miR-873-5p. The proteomic analysis showed
global proteomic alterations as a consequence of the MCD diet, as well
as a result of the treatment with anti-miR-873-5p (Figure 5B). A
complete list of the identiﬁed proteins signiﬁcantly regulated in the
analysis is provided in Supplementary Table 1. Hierarchical clustering
of this proteins with PERSEUS software and gene ontology (GO)
analysis using the STRING database were performed. Top regulated
proteins revealed an upregulation of GO-biological processes related to
oxidation-reduction processes (GO:0055114) and to metabolic andMOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comoxidative phosphorylation (OXPHOS) pathways, classiﬁed according to
the KEGG database (Suppl. Table2). Moreover, other identiﬁed proteins
were implicated in fatty acid degradation, antioxidation and oxidation-
reduction processes (Suppl. Tables 3 and 4).
Overall, the results obtained from the proteomic analysis suggest that
the most important processes altered in the mitochondria of MCDD fed
mice are related to oxidation-reduction and oxidative/phosphorylation,
function relying on ETC. These functions are recovered in the anti-miR-
873-5p treated mice in association with GNMT recovery.
To further explore the functionality and localization of GNMT in the ETC,
we performed BN-PAGE of 2% digitonin-solubilized mitochondrial liver
extracts. GNMT localized with Complex II (CII) (detected by succinatecess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 49
Original Articledehydrogenase (SDH) subunit A) in the ETC suggesting a potential role
of GNMT in CII functionality (Figure 5C).
Complex II or SDH is an important enzyme in mitochondrial metabolism
since it represents the hub where ETC and TCA converge. CII was
immunoprecipitated using liver mitochondrial extracts from the
different MCD mice and the interaction with GNMT was examined by
western blotting. GNMT co-precipitated with the CII from control diet
mice. A reduction in GNMT-CII interaction was detected in liver
mitochondria derived from MCDD fed mice, which was recovered in
the presence of anti-miR-873-5p (Figure 5D). These results suggest
that the induction of miR-873-5p during NAFLD regulates mitochon-
drial GNMT levels and its interaction with the CII, further indicating a
mitochondrial role of GNMT.
3.6. Mitochondrial GNMT regulates complex II activity in the ETC
In order to address the functionality of GNMT in CII, SDH activity was
measured in mitochondrial extracts derived from control and MCD
mice. A reduction of SDH activity in MCD liver was reverted after
blocking miR-873-5p (Figure 5E), suggesting that the presence of
GNMT in the mitochondria and its interaction with CII enhances its
activity. Interestingly, the role of GNMT in CII activity was further
conﬁrmed in Gnmt-KO mitochondrial liver extracts, where a strong
reduction of SDH activity compared with WT animals was detected
(Figure 5F).
Finally, we investigated the mechanism by which GNMT levels in the
mitochondria affect CII activity. GNMT is well known for participating in
the methionine cycle of one-carbon metabolism, where it metabolizes
SAMe to SAH, transferring the N-methyl group of SAMe to glycine to
generate sarcosine. Different metabolites of one-carbon metabolism,
including sarcosine and dimethylglycine (DMG) can be metabolized by
sarcosine dehydrogenase (SARDH) and dimethylglycineFigure 6: Mitochondrial induction of GNMT is associated with methionine cycle ac
cycle and one-carbon metabolism and its relation in mice fed on the MCD diet and treated w
p < 0.01 **.
50 MOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. Tdehydrogenase (DMGDH), respectively, in reactions producing FADH2,
in which two e are transferred to ubiquinone within the ETC. These
reactions are known as the electron transfer ﬂavoprotein: ubiquinone
reductase system (ETF:QO) and occur in the mitochondria, connecting
FAO, ETC, and one-carbon metabolism [32,33]. On the other hand,
mitochondrial CII transfers electrons to ubiquinone using FAD. Thus,
we have analyzed whether improvement in one-carbon metabolism in
the mitochondria due to GNMT rescue could be associated with the
transport of e in the ETC mediated by FAD and the increase of CII
activity. Based on this hypothesis, we analyzed one-carbon meta-
bolism in the liver of MCD mice. Mass spectrometry analysis revealed
increased abundance of metabolites of one-carbon metabolites after
anti-miR-873-5p treatment and GNMT recovery, including SAMe and
SAH, sarcosine and other intermediates such as betaine and DMG
(Figure 6). Interestingly, expression analysis of genes participating in
methionine cycle metabolism, such as Mat1a and CBS did not reveal
signiﬁcant changes in mice fed with the MCDD or treated with the anti-
miR-873-5p (data not shown), indicating that GNMT recovery by anti-
miR-873-5p therapy is sufﬁcient to restore methionine and one-carbon
metabolism in the liver. Globally, these results indicate an enhanced
ﬂux within the one-carbon metabolism particularly in those steps
occurring in the mitochondria, after mitochondrial GNMT recovery.
Overall, these results together with the localization of GNMT in the CII
suggest a new association between mitochondrial one-carbon meta-
bolism and ETC functionality regulated by GNMT.
4. DISCUSSION
With an estimated 1.8 billion people affected by NAFLD, this chronic
liver disease has turned into a global health problem with a worrying
tendency [1]. Hence, there is an ample pharmacological market aimingtivation. Log2 (fold-change) levels of metabolites and enzymes involved in methionine
ith the anti-miR-873-5p versus miR-Ctrl silencing. Data shown as average. p < 0.05 *;
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to treat NASH-derived complications and to identify non-invasive bio-
markers for the disease [3,34]. GNMT is the most important enzyme
regulating SAMe metabolism and is considered a marker of healthy
liver that is frequently downregulated in chronic liver disease, including
NAFLD [4,5], cirrhosis, and hepatocellular carcinoma [7e9]. GNMT
downregulation occurs during early stages of chronic liver disease;
thus, it is likely that its decrease is the cause - rather than the
consequence - of these pathologies. In this work, we show that miR-
873-5p upregulation (recently reported to target GNMT [7]) correlates
with GNMT downregulation in the liver of NAFLD/NASH patients and in
different murine models, identifying a relevant mechanism mediating
GNMT downregulation in NAFLD/NASH. Moreover, GNMT/miR-873-5p
levels in the liver correlate with the severity of disease in human NAFLD
patients, determined as NAS score, which is in accordance with our
previous study [7] and further suggests GNMT downregulation is an
early occurring event in liver disease that determines its progression.
Previous studies have shown that miR-873-5p is regulated by the
inﬂammatory mediator interleukin (IL)-17 [35], which is highly induced
and participates in the development of NAFLD/NASH, correlating with
the progression of the disease [36,37]. Accordingly, (IL)-17 could
explain the progressive increase in miR-873-5p we observe from
healthy to steatosis and NASH stages.
We evaluated the therapeutic potential of targeting miR-873-5p during
NAFLD development. MCDD represents an ideal model to study NAFLD
progression and its complications in the liver as it leads to more severe
NASH development than other models. MCDD mice show lipid accu-
mulation, necro-inﬂammation, and ﬁbrosis, resembling human pa-
thology. MiR-873-5p inhibition restored GNMT expression reducing
steatosis and NASH progression by decreasing different lipids. Even
though NAFLD is a multiple-hit disease, lipid overload is considered a
key driving event for its initiation and progression to more severe
stages. In addition to reduced lipid accumulation, anti-miR-873-5p
attenuated inﬂammatory and ﬁbrogenic processes in these mice.
Moreover, we provide evidence showing the global effect of miR-873-
5p on lipid metabolism is mediated by the regulation of mitochondrial
FAO in the hepatocytes, thereby suggesting an implication of GNMT in
mitochondrial functionality. Of note, although other targets of miR-873-
5p could be regulated in hepatocytes by anti-miR-873-5p, the lack of
effect observed in Gnmt-KO hepatocytes in vitro and in the Gnmt-KO
mice indicates Gnmt is the main target gene regulated by this
microRNA under steatotic situation. Unfortunately, only oleic acid in-
cubation could be used as in vitro model for miR-873-5p inhibition in
Gnmt-KO hepatocytes, as far as the use of the MDMC in these he-
patocytes would not produce similar effect due to de intrinsic high
methionine levels of Gnmt-KO hepatocytes [28]. More importantly, the
lack of effect in FAO oxidation upon miR-873-5p inhibition in Gnmt-KO
livers strengths our hypothesis of the role of GNMT in mitochondrial
functionality. Even though the Gnmt-KO may differ from our working
MCDD model in terms of the mechanisms driving fatty liver develop-
ment and mainly due to the high amount of SAMe levels in this mouse,
we have described that these mice develop steatosis and liver
inﬂammation by this time [28]; thus, other potential miR-873-5p tar-
gets involved in FAO should arise in this model upon anti-miR-873-5p
treatment. Altogether, our results, show that GNMT is necessary for
appropriate mitochondrial function and b-oxidation, and this process is
altered by miR-873-5p targeting of Gnmt.
While increased mitochondrial FAO is frequently observed in steatosis,
probably as a compensatory mechanism to reduce the lipid burden
[12], the progression of the disease leads to decreased oxidative ca-
pacity due to an uncoupling between b-oxidation, TCA cycle, and ETC,
frequently resulting in inefﬁcient lipid metabolism and ROSMOLECULAR METABOLISM 29 (2019) 40e54  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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miR-873-5p inhibition increases mitochondrial b-oxidation without
increasing oxidative stress, which may implicate improved mito-
chondrial functionality and efﬁcient e ﬂow in the ETC. We also show
that GNMT is regulated in the mitochondria, where no function has
been previously reported. GNMT interacts and regulates the activity of
CII, which plays a crucial role in metabolism participating both in the
ETC and the TCA cycle and contributing to ROS formation [38].
Decreased CII activity observed in MCDD-fed mice is in accordance
with previous results [39e42] and may implicate impaired e ﬂow
through the ETC and decreased TCA cycle activity. On the contrary,
targeting miR-873-5p and recovery of GNMT levels induces CII activity,
which enhances ETC and global mitochondrial functionality, allowing a
continuous lipid burning and restraining NASH progression.
As the main catabolic enzyme for SAMe, misbalance in GNMT levels
may be regulating methionine metabolism in the mitochondria in our
experimental model. Here we show that GNMT recovery in the mito-
chondria is associated with an increased amount of methionine cycle
metabolites, which suggests improved methionine and one-carbon
metabolism. Surprisingly, despite these global changes in methio-
nine and one-carbon metabolism produced in mice fed the MCDD and
also in those treated with the anti-miR-873-5p, lack of gene expres-
sion regulation was observed in other enzymes that participate in the
cycle besides GNMT, which highlights the importance of GNMT in the
regulation of these processes. Moreover, sarcosine (the product of
GNMT enzymatic activity) and other metabolites increased after miR-
873-5p inhibition. Besides participating in the methionine cycle, sar-
cosine and DMG are used as substrates by the electron transfer
ﬂavoprotein (ETF) system in reactions that produce FADH2 and transfer
2e to ubiquinone, linking mitochondrial FAO, one-carbon metabolism,
and the ETC [32,33]. Our results indicate that the recovery of mito-
chondrial GNMT enhances one-carbon metabolism and suggest that
interaction of GNMT with CII of the ETC, drives a metabolic adaptation
in mitochondria, linking b-oxidation, ETF, and ETC. Based on our re-
sults, we propose that these adaptations may lead to improved
mitochondrial functionality and OXPHOS processes, thereby reducing
NASH progression.
In conclusion, the present study demonstrates that enhancing mito-
chondrial b-oxidation by relieving miR-873-5p repression on GNMT
may be an effective mechanism to reduce lipid burden in the liver.
Thus, targeting miR-873-5p may be of wide applicability for NAFLD
therapies. Moreover, given the importance of GNMT in liver health and
its downregulation in chronic liver disease, targeting its expression by
anti-miR-873-5p may represent a novel strategy to efﬁciently treat
liver diseases in early and advanced stages.
5. CONCLUSION
Our study describes the contribution of GNMT to mitochondrial func-
tionality in hepatocytes through the binding and regulation of Complex
II in the ETC, promoting fatty acid b-oxidation. Furthermore, we provide
evidence for the steatotic role of miR-873-5p, a speciﬁc repressor of
GNMT expression which is upregulated in the liver of NAFLD and NASH
patients and in murine models. Regulation of GNMT by targeting miR-
873-5p ameliorates fatty liver disease by improving mitochondrial
functionality.
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